Connection

Michael Zile to Natriuretic Peptide, Brain

Back to Details
This is a "connection" page, showing publications Michael Zile has written about Natriuretic Peptide, Brain.
Michael Zile
Connection Strength
4.138
Natriuretic Peptide, Brain
  1. Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. Clin Cardiol. 2020 Dec; 43(12):1501-1510.
    View in: PubMed
    Score: 0.700
  2. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 06; 68(22):2425-2436.
    View in: PubMed
    Score: 0.538
  3. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
    View in: PubMed
    Score: 0.179
  4. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart?Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020 05; 8(5):372-381.
    View in: PubMed
    Score: 0.169
  5. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart?Failure Position Paper. JACC Heart Fail. 2020 05; 8(5):347-358.
    View in: PubMed
    Score: 0.169
  6. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 02; 13(2):e006541.
    View in: PubMed
    Score: 0.168
  7. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The?PARADIGM-HF?Trial. J Am Coll Cardiol. 2019 03 26; 73(11):1264-1272.
    View in: PubMed
    Score: 0.157
  8. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circ Heart Fail. 2019 03; 12(3):e005766.
    View in: PubMed
    Score: 0.157
  9. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019 01; 21(1):40-49.
    View in: PubMed
    Score: 0.155
  10. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.142
  11. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 11 29; 134(22):1785-1787.
    View in: PubMed
    Score: 0.134
  12. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. Semin Thorac Cardiovasc Surg. 2016 Summer; 28(2):320-328.
    View in: PubMed
    Score: 0.130
  13. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial. J Card Fail. 2016 Apr; 22(4):283-93.
    View in: PubMed
    Score: 0.125
  14. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2015 Jun; 3(6):478-486.
    View in: PubMed
    Score: 0.121
  15. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail. 2015 Aug; 17(8):809-17.
    View in: PubMed
    Score: 0.120
  16. Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens. 2013 Oct; 26(10):1234-41.
    View in: PubMed
    Score: 0.106
  17. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011 Sep; 4(5):569-77.
    View in: PubMed
    Score: 0.092
  18. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010 Feb; 16(2):128-34.
    View in: PubMed
    Score: 0.082
  19. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. Circ Heart Fail. 2023 03; 16(3):e010111.
    View in: PubMed
    Score: 0.051
  20. Baroreflex activation therapy with the Barostim? device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. Eur J Heart Fail. 2022 09; 24(9):1665-1673.
    View in: PubMed
    Score: 0.049
  21. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022 03; 24(3):497-509.
    View in: PubMed
    Score: 0.048
  22. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clin Res Cardiol. 2021 Aug; 110(8):1334-1349.
    View in: PubMed
    Score: 0.046
  23. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clin Res Cardiol. 2021 Aug; 110(8):1234-1248.
    View in: PubMed
    Score: 0.044
  24. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020 03; 22(3):528-538.
    View in: PubMed
    Score: 0.041
  25. Health-Related Quality of Life in Heart?Failure With Preserved Ejection?Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 10; 7(10):862-874.
    View in: PubMed
    Score: 0.040
  26. Differential Impact of Heart Failure With?Reduced Ejection Fraction on?Men?and?Women. J Am Coll Cardiol. 2019 01 08; 73(1):29-40.
    View in: PubMed
    Score: 0.039
  27. Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. Int J Cardiol. 2018 Sep 01; 266:187-192.
    View in: PubMed
    Score: 0.037
  28. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017 Feb 21; 135(8):724-735.
    View in: PubMed
    Score: 0.034
  29. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. Eur J Heart Fail. 2016 08; 18(8):1021-31.
    View in: PubMed
    Score: 0.032
  30. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan 06; 131(1):54-61.
    View in: PubMed
    Score: 0.029
  31. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014 Nov; 7(6):953-9.
    View in: PubMed
    Score: 0.029
  32. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014 Jul; 16(7):817-25.
    View in: PubMed
    Score: 0.028
  33. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail. 2014 Jun; 16(6):671-7.
    View in: PubMed
    Score: 0.028
  34. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J. 2014 Jan; 35(1):42-7.
    View in: PubMed
    Score: 0.027
  35. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013 Sep; 15(9):1062-73.
    View in: PubMed
    Score: 0.026
  36. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20; 380(9851):1387-95.
    View in: PubMed
    Score: 0.025
  37. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011 Jan; 4(1):27-35.
    View in: PubMed
    Score: 0.022
  38. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005 Oct; 11(8):576-85.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.